Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Acute Respiratory Infections

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%

All‐cause mortality · patients at high risk of severe respiratory syncytial virus infection

Palivizumab showed no clear difference in all‐cause mortality compared with placebo (moderate certainty).

1 finding from 1 review

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children 2013 · Cochrane Headline outcomes only
RR 0.69 [0.42, 1.15]
3 studies · 2831 participants
Moderate

All‐cause mortality · patients at high risk of severe respiratory syncytial virus infection

Palivizumab showed no clear difference in all‐cause mortality compared with motavizumab (moderate certainty).

1 finding from 1 review

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children 2013 · Cochrane Headline outcomes only
RR 0.74 [0.38, 1.43]
4 studies · 8265 participants
Moderate